Get the Stockscreener App
5.2269
0.52%
0.0269
Orchestra Biomed Holdings Inc stock is traded at $5.2269, with a volume of 6,995.
It is up +0.52% in the last 24 hours and up +1.10% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$5.20
Open:
$5.29
24h Volume:
6,995
Relative Volume:
0.08
Market Cap:
$196.69M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-3.4846
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
-7.81%
1M Performance:
+1.10%
6M Performance:
-18.07%
1Y Performance:
-9.57%
1-Day Range:
$5.23
$5.3885
1-Week Range:
$5.20
$5.98
52-Week Range:
$3.96
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
5.23 | 196.69M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.87 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.47 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.33 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.04 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.98 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Orchestra BioMed to Participate in Upcoming Investor Conferences - MyChesCo
Orchestra BioMed to Present at Upcoming Investor Conferences - GlobeNewswire
3 Major Healthcare Conferences Where Orchestra BioMed Will Share Its Growth Story - StockTitan
Dr. Vivek Reddy Joins Orchestra BioMed to Lead Breakthrough Hypertension Study - MyChesCo
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive - GlobeNewswire
Mount Sinai's Top Cardiac Expert Takes Helm of Groundbreaking Hypertension Treatment Study - StockTitan
Orchestra BioMed (NASDAQ:OBIO) Shares Up 5.1%Time to Buy? - MarketBeat
Orchestra BioMed Unveils Groundbreaking Data on AVIM Therapy’s Potential to Prevent Heart Failure - MSN
SG Americas Securities LLC Has $51,000 Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed (NASDAQ:OBIO) Trading 5.1% Higher – Here’s Why - Defense World
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Decline in Short Interest - Defense World
How the (OBIO) price action is used to our Advantage - Stock Traders Daily
Individual investors among Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest stockholders and were hit after last week's 11% price drop - Simply Wall St
Orchestra BioMed Says AVIM Therapy Improves Echo Markers of Diastolic Dysfunction - Marketscreener.com
Orchestra BioMed Announces Data Demonstrating Favorable - GlobeNewswire
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference - GlobeNewswire
Clinical Data: Orchestra BioMed's AVIM Therapy Shows Significant Heart Failure Prevention Benefits | OBIO Stock News - StockTitan
Orchestra BioMed Welcomes Christopher Cleary to Board of Directors - MSN
Orchestra BioMed Announces Appointment of Former Medtronic - GlobeNewswire
Orchestra BioMed Appoints New Director Amid Board Changes - TipRanks
Christopher Cleary Joins Orchestra BioMed Board of Directors, Enhancing Strategic Leadership in Medical Device Innovations - Nasdaq
Medtronic M&A Veteran Who Led $60B+ in Deals Joins Orchestra BioMed Board - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Orchestra BioMed Reports Q3 2024 Results, Advances Key Clinical Programs - MSN
Barclays PLC Increases Stock Position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
When (OBIO) Moves Investors should Listen - Stock Traders Daily
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Jane Street Group LLC - Defense World
(OBIO) Investment Analysis - Stock Traders Daily
Geode Capital Management LLC Purchases 11,002 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Barclays PLC Increases Stake in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St
Orchestra BioMed (NASDAQ:OBIO) Coverage Initiated by Analysts at Barclays - Defense World
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight Recommendation - MSN
Orchestra BioMed shares get shot in the arm on solid clinical trial data - Mugglehead
Orchestra BioMed Up 49% After Barclays Starts Coverage With $16 Target - MarketWatch
Stock market news: Rain Oncology +371.17%, SuperCom +75.93% among top gainers during mid day trading - Business Upturn
Orchestra BioMed (NASDAQ:OBIO) Now Covered by Barclays - MarketBeat
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Orchestra Orchestra BioMed stock rated Overweight on novel medtech model By Investing.com - Investing.com Nigeria
State Street Corp Has $2.21 Million Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra Biomed CEO David Hochman buys $18,640 in common stock By Investing.com - Investing.com Australia
Orchestra Biomed CEO David Hochman buys $18,640 in common stock - Investing.com India
Insider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Purchases 4,000 Shares of Stock - MarketBeat
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) top owners are individual investors with 26% stake, while 22% is held by hedge funds - Yahoo Finance
Orchestra BioMed CFO Taylor Lawrence buys $4,830 in company stock - Investing.com
Orchestra Biomed CEO David Hochman buys $24,550 in stock By Investing.com - Investing.com Canada
Orchestra Biomed CEO David Hochman buys $24,550 in stock - Investing.com India
Insider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Acquires 5,000 Shares of Stock - MarketBeat
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):